Gastroparesis (GP) is a disorder of gastric motilityfunction characterized by a delay in gastric emptying, frequently associated with chronic nausea and vomiting, early satiety, postprandial fullness, abdominal pain, and malnutrition that may require nutritional support. GP has a devastating impact on quality of life and predominantly affects younger women. In the past 5 years, the Gastroparesis Clinical Research Consortium (GpCRC) has made a series of important contributions to improve our understanding of this disorder and these observations have advenced the goals of helping our patients and their physicians as well as meeting the goals to improve the management of gastroparesis. We therefore propose the following specific aims for this application: # 1: To complete the ongoing and approved studies initiated by the GpCRC;# 2: To maintain, expand, and refine the GP Registry, and to address important questions related to the pathogenesis, complications and clinical outcome in GP patients by further in-depth analysis of GpR clinical data and biosamples;# 3: To conduct new multicenter studies of gastroparesis investigating the etiology, pathogenesis, diagnosis, and treatment options. TTUHSC is proposing a double-blind, """"""""time- to- failure"""""""" placebo controlled trial (phase 1) of 4 months duration with """"""""a best clinical care"""""""" follow up (phase 2) of 8 months duration study to evaluate the efficacy and safety of domperidone in gastroparesis. The principal objectives of this multicenter, randomized trial are to:1) Document the efficacy of domperidone in GP patients;2) Compare domperidone's efficacy in diabetics vs. idiopathic etiologies;3) Investigate the optimal dose or doses;4) Explore the demographic and clinical factors which predict the best clinical response;5) Asses safety. Unlike the FDA approved prokinetic agent, metoclopramide, which is also a dopamine antagonist, with antiemetic and prokinetic properties, domperidone has an exellent safety profile for long- term administration. Due to the very restricted accessibility of domperidone in US (through the FDA protocol) many questions related to its efficacy, therapeutic dosing and side effects still remain unanswered. Therefore, we have proposed this study to resolve these questions.
This research underscores the public health significance of gastroparesis (GP) including;the need to develop effective methods for management of GP, the need to identify patients who are at risk of progression to more severe GP, to identify the key cellular changes that lead to GP, and to initiate several novel, therapeutic trials that have the potential to directly influence the quality of life of patients with GP and also in turn provide new knowledge for physicians to treat these patients.
|Angeli, Timothy R; Cheng, Leo K; Du, Peng et al. (2015) Loss of Interstitial Cells of Cajal and Patterns of Gastric Dysrhythmia in Patients With Chronic Unexplained Nausea and Vomiting. Gastroenterology 149:56-66.e5|
|Neshatian, L; Gibbons, S J; Farrugia, G (2015) Macrophages in diabetic gastroparesis--the missing link? Neurogastroenterol Motil 27:7-18|
|Pasricha, Pankaj J; Yates, Katherine P; Nguyen, Linda et al. (2015) Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. Gastroenterology 149:1762-1774.e4|
|Bernard, C E; Gibbons, S J; Mann, I S et al. (2014) Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil 26:1275-84|
|Iorio, Raffaele; Lucchinetti, Claudia F; Lennon, Vanda A et al. (2013) Intractable nausea and vomiting from autoantibodies against a brain water channel. Clin Gastroenterol Hepatol 11:240-5|
|Farrugia, G; Weinshilboum, R M (2013) Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther 94:204-6|
|Gibbons, S J; Verhulst, P-J; Bharucha, A et al. (2013) Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics. Aliment Pharmacol Ther 38:689-702|
|Parkman, Henry P; Van Natta, Mark L; Abell, Thomas L et al. (2013) Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 310:2640-9|
|Parkman, Henry P; Yates, Katherine; Hasler, William L et al. (2013) Cholecystectomy and clinical presentations of gastroparesis. Dig Dis Sci 58:1062-73|
|Hasler, W L; Wilson, L A; Parkman, H P et al. (2013) Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil 25:427-38, e300-1|
Showing the most recent 10 out of 25 publications